Log in

Relevant bibliographies by topics / Hydergine / Journal articles

Journal articles on the topic 'Hydergine'

To see the other types of publications on this topic, follow the link: Hydergine.

Author: Grafiati

Published: 26 July 2024

Last updated: 28 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Hydergine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Nussenblatt, RobertB, HowardA Austin, AlanG Palestine, and HarryG Preuss. "HYDERGINE AND CYCLOSPORIN NEPHROTOXICITY." Lancet 327, no. 8491 (May 1986): 1220–21. http://dx.doi.org/10.1016/s0140-6736(86)91209-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

TAMURA, TAKASHI, TAIICHI SATOH, HISANORI MINAKAMI, and TARO TAMADA. "Effect of Hydergine in Hyperprolactinemia." Journal of Clinical Endocrinology & Metabolism 69, no. 2 (August 1989): 470–74. http://dx.doi.org/10.1210/jcem-69-2-470.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Guida, Charles V. "Review: Hydergine is effective for dementia." ACP Journal Club 122, no. 1 (January 1, 1995): 17. http://dx.doi.org/10.7326/acpjc-1995-122-1-017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kho, T. L., R. Kengen, K. M. L. Leunissen, J. Teule, and J. P. Van Hooff. "HYDERGINE AND REVERSIBILITY OF CYCLOSPORIN NEPHROTOXICITY." Lancet 328, no. 8503 (August 1986): 394–95. http://dx.doi.org/10.1016/s0140-6736(86)90077-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Hydergine-LC appears ineffective in Alzheimer's disease." Inpharma Weekly &NA;, no. 751 (August 1990): 9–10. http://dx.doi.org/10.2165/00128413-199007510-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Romero, R., A. Felip, J. M. Llibre, J. Bonet, and A. Caralps. "Co-Dergocrine Mesylate (Hydergine) and Hypertensive Emergencies." Nephron 51, no. 1 (1989): 127–28. http://dx.doi.org/10.1159/000185270.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Schneider, L. S., and J. T. Olin. "Overview of Clinical Trials of Hydergine in Dementia." Archives of Neurology 51, no. 8 (August 1, 1994): 787–98. http://dx.doi.org/10.1001/archneur.1994.00540200063018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kuskowski, Michael A., Gerald Morley, Stephen M. Malone, Maurice W. Dysken, and Amy Okaya. "Hydergine Treatment and Psychophysiological Measures in Primary Degenerative Dementia." Journal of Geriatric Psychiatry and Neurology 3, no. 1 (January 1990): 41–47. http://dx.doi.org/10.1177/089198879000300109.

Full text

Abstract:

Changes in smooth pursuit eye movements and the P300 component of the auditory evoked potential were studied in patients with primary degenerative dementia during a double-blind, placebo-controlled study of ergoloid mesylates (Hydergine). After 18 weeks of treatment, P300 latency and amplitude, recorded at three scalp electrode sites, had not changed significantly. Smooth pursuit gain was elevated for the drug group under some stimulus conditions, suggesting a normalization of pursuit eye movement functioning. However, the results of several other measures of the quality of pursuit eye movements failed to corroborate this finding. ( J Geriatr Psychiatry Neurol 1990; 3:41-47).

APA, Harvard, Vancouver, ISO, and other styles

9

Sobky, A. El, M. El Shazly, A. K. Darwish, T. Davies, K. Griffin, and M. S. Keshavan. "Hydergine effect on prolactin and reaction time in dementia." Biological Psychiatry 21, no. 12 (October 1986): 1229–30. http://dx.doi.org/10.1016/0006-3223(86)90230-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lon, S., M. D. Schneider, T. Jason, and A. M. Olin. "Meta-analysis of hydergine clinical trials in primary dementia." Neurobiology of Aging 13 (January 1992): S123. http://dx.doi.org/10.1016/0197-4580(92)90613-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

TAKEHARA, KAZUHIKO. "Clinical usefulness of hydergine tablets for Raynaud phenomenon in scleroderma." Nishi Nihon Hifuka 58, no. 5 (1996): 840–42. http://dx.doi.org/10.2336/nishinihonhifu.58.840.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

BECHGAARD, POUL, and LEIF PAULSEN. "Dihydrogenated Ergot Alkaloids (Hydergine) in the Treatment of Essential Hypertension." Acta Medica Scandinavica 145, no. 3 (April 24, 2009): 189–99. http://dx.doi.org/10.1111/j.0954-6820.1953.tb07010.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Rodriguez, D. V., D. F. Peeler, R. R. Smith, T. S. Sanders, and J. B. Beckett. "ATTENUATION OF ISCHEMIA-REPERFUSION INJURY IN GERBIL HIPPOCAMPUS BY HYDERGINE." Southern Medical Journal 84, Supplement (September 1991): 42. http://dx.doi.org/10.1097/00007611-199109001-00143.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Datta, Kapal D., Richard C. Evenson, Patrick J. Gannon, and Earl P. Dick. "Efficacy of oral hydergine (ergoloid mesylates) in alcohol related encephalopathy." Progress in Neuro-Psychopharmacology and Biological Psychiatry 11, no. 1 (January 1987): 87–90. http://dx.doi.org/10.1016/0278-5846(87)90035-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Thompson, Troy L., Christopher M. Filley, Wayne D. Mitchell, Kathleen M. Culig, Mary LoVerde, and Richard L. Byyny. "Lack of Efficacy of Hydergine in Patients with Alzheimer's Disease." New England Journal of Medicine 323, no. 7 (August 16, 1990): 445–48. http://dx.doi.org/10.1056/nejm199008163230704.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Harirî, N., B. Falakal, and O. Algan. "THE EFFECTS OF HYDERGINE ON THE SYNAPTIC PLASTICITY OF AGED RATS." Clinical Neuropharmacology 15 (1992): 560B. http://dx.doi.org/10.1097/00002826-199202001-01093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Qizilbash, Nawab. "The Cochrane Dementia and Cognitive Impairment Group." Reviews in Clinical Gerontology 7, no. 2 (February 1997): 183–88. http://dx.doi.org/10.1017/s0959259897000208.

Full text

Abstract:

Over 2000 randomized trials are reported in the literature for the treatment of dementia and cognitive decline. Yet the responses to the question, ‘Which treatments are effective in dementia?’ are likely to be various and conflicting. Wide variation in practice exists, and for drug therapy, where information is more readily available, different treatments are used in different countries. For example, only one drug (Hydergine) is licensed in the UK for dementia, though rarely used, while there are over 30 drugs in use in Japan for dementia and cognitive decline, five in Spain, and two in the USA. This inconsistency is likely to be even greater for interventions of psychological and behavioural therapies, environmental therapy and the organization of care.

APA, Harvard, Vancouver, ISO, and other styles

18

PÖLDRE, ARVO. "Two-Year Results of Hydergine Therapy in Hypertension and Other Circulatory Disturbances." Acta Medica Scandinavica 155, no. 6 (April 24, 2009): 437–48. http://dx.doi.org/10.1111/j.0954-6820.1956.tb14392.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

ROTHLIN, E., A. CERLETTI, and H. EMMENEGGER. "Experimental Psycho-neurogenic Hypertension and its Treatment with Hydrogenated Ergot Alkaloids (Hydergine)." Acta Medica Scandinavica 154, S312 (April 24, 2009): 27–35. http://dx.doi.org/10.1111/j.0954-6820.1956.tb16947.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Sunderland, T., K. T. Putnam, R. Martinez, A. Mellow, B. A. Lawlor, B. Vitiello, S. Molchan, R. M. Cohen, and H. Weingartner. "COGNITIVE EFFECTS OF LONG-TERM DEPRENYL AND HYDERGINE IN ALZHEIMERʼS DISEASE PATIENTS." Clinical Neuropharmacology 15 (1992): 161B. http://dx.doi.org/10.1097/00002826-199202001-00310.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

lmperato, Assunta, Maria Carmen Obinu, Laura Dazzi, Giovanna Carta, Maria Stefania Mascia, Maria Antonietta Casu, and Gian Luigi Gessa. "Co-dergocrine (Hydergine) regulates striatal and hippocampal acetylcholine release through D2 receptors." NeuroReport 5, no. 6 (February 1994): 674–76. http://dx.doi.org/10.1097/00001756-199402000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Kitaoku, Yoshiyuki, Takashi Matsunaga, and Hiroyuki Kitamura. "Clinical Study of Ternelin Therapy and Ternelin and Hydergine Therapy for Tinnitus." Practica Oto-Rhino-Laryngologica 88, no. 5 (1995): 645–56. http://dx.doi.org/10.5631/jibirin.88.645.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Ehrly, A. M., and K. Saeger-Lorenz. "The effect of Hydergine® on the filterability of erythrocytes from hyperosmolar blood." Clinical Hemorheology and Microcirculation 12, no. 2 (1992): 223–28. http://dx.doi.org/10.3233/ch-1992-12207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

SINGH, S. K., J. N. M. IJZERMANS, R. L. MARQUET, R. W. F. DE BRUIN, D. L. WESTBROEK, and J. JEEKEL. "EFFECT OF HYDERGINE ON CYCLOSPORINE-INDUCED NEPHROTOXICITY IN A RAT KIDNEY TRANSPLANTATION MODEL." Transplantation 43, no. 4 (April 1987): 593–94. http://dx.doi.org/10.1097/00007890-198704000-00033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

KAPPERT, ARNOLD, CARL-HENRIK SKOGLUND, ANDERS BERGHOLTZ, and GUSTAV NYLIN. "The Effect of Hydergine (CCK) on Reflex Vasoconstriction and Reflex Blood Pressure Stimulation." Acta Medica Scandinavica 141, no. 6 (April 24, 2009): 440–50. http://dx.doi.org/10.1111/j.0954-6820.1952.tb14234.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Werneke, Ursula, Trevor Turner, and Stefan Priebe. "Complementary medicines in psychiatry." British Journal of Psychiatry 188, no. 2 (February 2006): 109–21. http://dx.doi.org/10.1192/bjp.188.2.109.

Full text

Abstract:

BackgroundThe use of complementary medicines in those with mental health problems is well documented. However, their effectiveness is often not established and they may be less harmless than commonly assumed.AimsTo review the complementary medicines routinely encountered in psychiatric practice, their effectiveness, potential adverse effects and interactions.MethodElectronic and manual literature search on the effectiveness and safety of psychotropic complementary medicines.ResultsPotentially useful substances include ginkgo and hydergine as cognitive enhancers, passion flower and valerian as sedatives, St John's wort and sadenosylmethionine as antidepressants, and selenium and folate to complement antidepressants. The evidence is less conclusive for the use of omega-3 fatty acids as augmentation treatment in schizophrenia, melatonin for tardive dyskinesia and 18-methoxycoronaridine, an ibogaine derivative, for the treatment of cocaine and heroin addiction.ConclusionsSystematic clinical trials are needed to test promising substances. Meanwhile, those wishing to take psychotropic complementary medicines require appropriate advice.

APA, Harvard, Vancouver, ISO, and other styles

27

Izumiyama, K., and K. Kogure. "Effect of dihydroergotoxine mesylate (Hydergine®) on delayed neuronal death in the gerbil hippocampus." Acta Neurologica Scandinavica 78, no. 3 (September 1988): 214–20. http://dx.doi.org/10.1111/j.1600-0404.1988.tb03649.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Huber, F., S. Köberle, H. Prestele, and R. Spiegel. "Effects of long-term ergoloid mesylates (‘Hydergine’) administration in healthy pensioners: 5-year results." Current Medical Research and Opinion 10, no. 4 (January 1986): 256–79. http://dx.doi.org/10.1185/03007998609110447.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Amenta, Daniela, Fabio Ferrante, Flavio Franch, and Francesco Amenta. "Effects of Long-Term Hydergine® Administration on Lipofuscin Accumulation in Senescent Rat Brain." Gerontology 34, no. 5-6 (1988): 250–56. http://dx.doi.org/10.1159/000212963.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Steurer, G., P. Fitscha, K. Ettl, and H. Sinzinger. "Effects of hydergine on platelet deposition on “active” human carotid artery lesions and platelet function." Thrombosis Research 55, no. 5 (September 1989): 577–89. http://dx.doi.org/10.1016/0049-3848(89)90390-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Boulat, O., P. Waldmeier, and L. Maitre. "3,4-Dihydroxyphenylacetic acid (DOPAC) as an index of noradrenaline turnover: Effects of hydergine� and vincamine." Journal of Neural Transmission 82, no. 3 (October 1990): 181–95. http://dx.doi.org/10.1007/bf01272761.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Hariri, N. I., A. Büyüköztürk, L. Kanit, B. Ersöz, and G. Menteş. "The effects of hydergine on the MAO activity of the aged and adult rat brain." European Neuropsychopharmacology 4, no. 3 (September 1994): 399–400. http://dx.doi.org/10.1016/0924-977x(94)90231-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Büyüköztürk, As'lihan, Lütfiye Kanıt, Biltan Ersöz, Gülriz Menteş, and Nuran İ. Hariri. "The effects of hydergine on the MAO activity of the aged and adult rat brain." European Neuropsychopharmacology 5, no. 4 (December 1995): 527–29. http://dx.doi.org/10.1016/0924-977x(95)80014-s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

NAGASAWA, HARUO, KYUYA KOGURE, KOICHIRO KAWASHIMA, TATSUO IDO, MASATOSHI ITOH, and JUN HATAZAWA. "Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography." Tohoku Journal of Experimental Medicine 162, no. 3 (1990): 225–33. http://dx.doi.org/10.1620/tjem.162.225.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Ammon, Ronald, Rehka Sharma, Steven R. Gambert, and Krishan Lal Gupta. "Hydergine revisited: A statistical analysis of studies showing efficacy in the treatment of cognitively impaired elderly." AGE 18, no. 1 (January 1995): 5–9. http://dx.doi.org/10.1007/bf02434076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Bullock, R. "Review: hydergine leads to greater global improvement and greater improvement on comprehensive rating scales in dementia." Evidence-Based Mental Health 2, no. 1 (February 1, 1999): 15. http://dx.doi.org/10.1136/ebmh.2.1.15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Shoptaw, Steven, Donnie W. Watson, Chris Reiber, Richard A. Rawson, Margaret A. Montgomery, Maria D. Majewska, and Walter Ling. "Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST)." Addiction 100 (March 2005): 78–90. http://dx.doi.org/10.1111/j.1360-0443.2005.00991.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Orma, H., and S. Vannas. "OBSERVATIONS ON THE USE OF PH 203 AND HYDERGINE IN SOME CIRCULATORY DISTURBANCES OF THE FUNDUS AND VASCULAR RETINOPATHY." Acta Ophthalmologica 36, no. 4 (May 27, 2009): 734–49. http://dx.doi.org/10.1111/j.1755-3768.1958.tb02284.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Meier-Ruge, W. "Effects of prolonged co-dergocrine mesylate (Hydergine®) treatment on local cerebral glucose uptake in aged Fischer 344 rats." Archives of Gerontology and Geriatrics 5, no. 1 (April 1986): 65–77. http://dx.doi.org/10.1016/0167-4943(86)90009-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Bertoni-Freddari, C., C. Giuli, C. Pieri, D. Paci, L. Amadio, M. Ermini, and A. Dravid. "The Effect of Chronic Hydergine Treatment on the Plasticity of Synaptic Junctions in the Dentate Gyms of Aged Rats." Journal of Gerontology 42, no. 5 (September 1, 1987): 482–86. http://dx.doi.org/10.1093/geronj/42.5.482.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Rouy, L. M., A. M. Douillon, R. Compan, and Y. Wolmark. "Ergoloid mesylates ('Hydergine') in the treatment of mental deterioration in the elderly: A 6-month double-blind, placebo-controlled trial." Current Medical Research and Opinion 11, no. 6 (January 1989): 380–89. http://dx.doi.org/10.1185/03007998909110139.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Serino, Anthony, Kwai Kan, Kimberly Graves, Christopher Kule, and Adam Anthony. "Age, strain, and semi-chronic hydergine treatment effects on motor activity and neuronal nucleic acid-protein metabolism in male mice." Life Sciences 67, no. 12 (August 2000): 1489–505. http://dx.doi.org/10.1016/s0024-3205(00)00732-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Hochberg, Ingrid. "MORPHOLOGICAL STUDIES ON THE EFFECT OF HYDERGINE ON THE ANTERIOR HORN CELLS AND THE CELLS OF NUCLEI VII, X, AND XII." Acta Pathologica Microbiologica Scandinavica 32, no. 2 (August 18, 2009): 300–315. http://dx.doi.org/10.1111/j.1699-0463.1953.tb00255.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Schoups, A. A., V. K. Saxena, K. Tombeur, and W. P. De Potter. "Facilitation of the release of noradrenaline and neuropeptide Y by the α2-adrenoceptor blocking agents idazoxan and hydergine in the dog spleen." Life Sciences 42, no. 5 (January 1988): 517–23. http://dx.doi.org/10.1016/0024-3205(88)90092-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Amenta, Francesco, Anne-Lise Jaton, and Alberto Ricci. "Effect of long term hydergine treatment on the age-dependent loss of mossy fibers and of granule cells in the rat hippocampus." Archives of Gerontology and Geriatrics 10, no. 3 (May 1990): 287–96. http://dx.doi.org/10.1016/0167-4943(90)90030-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Saletu, B., J. Grünberger, P. Anderer, L. Linzmayer, G. Pakesch, and G. Zyhlarz. "Effect-kinetics on brain protection of two codergocrine-mesylate preparations (Aramexe retard® and Hydergine®) by EEG mapping and psychometry under hypoxia." Archives of Gerontology and Geriatrics 18, no. 2 (March 1994): 81–99. http://dx.doi.org/10.1016/0167-4943(94)00533-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Arrigo, A., R. Casale, I. Giorgi, C. Guarnaschelli, and F. Zelaschi. "Effects of Intravenous High Dose Co-Dergocrine Mesylate (‘Hydergine’®) in Elderly Patients with Severe Multi-Infarct Dementia: a Double-Blind, Placebo-Controlled Trial." Current Medical Research and Opinion 11, no. 8 (January 1989): 491–500. http://dx.doi.org/10.1185/03007998909110460.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Unseld, H. "Vasospasmus nach Leberruptur, Dopamin- und Hydergin®-Infusion." AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie 20, no. 06 (December 1985): 339–41. http://dx.doi.org/10.1055/s-2007-1003135.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Gripwall, E., and A. Pöldre. "Einige Erfahrungen aus der Behandlung von essentieller Hypertonie mit Hydergin." Acta Medica Scandinavica 154, S312 (April 24, 2009): 245–47. http://dx.doi.org/10.1111/j.0954-6820.1956.tb16991.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Thienhaus, Ole J., Beverly G. Wheeler, Sandra Simon, Frank P. Zemlan, and James T. Hartford. "A Controlled Double-Blind Study of High-Dose Dihydroergotoxine Mesylate (HydergineR) in Mild Dementia." Journal of the American Geriatrics Society 35, no. 3 (March 1987): 219–23. http://dx.doi.org/10.1111/j.1532-5415.1987.tb02312.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!